skip to Main Content

Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer’s Disease


Brief Summary:

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets
an abnormal protein in the brain found in people with Alzheimer’s Disease (AD).


Inclusion Criteria:

– Participants must have gradual and progressive change in memory function for >6

– Participants must have a family member or close friend who is with you at least 10
hours per week and can attend study appointments.

Exclusion Criteria:

– Participants must not have significant neurological disease affecting the nervous
system, other than AD, that affects cognition or may affect completion of the study.

– Participants must not have serious or unstable illness that could interfere with the
analysis of the study or has a life expectancy <24 months. - Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread. - Participants must not have serious risk for suicide. - Participants must not have history of drug or alcohol use disorder within the last 2 years. - Participants must not have multiple severe drug allergies - Participants must not have HIV, Hepatitis B or Hepatitis C - Participants must not be receiving gamma globulin (IgG) or intravenous immunoglobulin (IVIG) therapy


  • Pharmacology Research Institute, Encino, California, United States, 91316
  • Fullerton Neurology and Headache Center, Fullerton, California, United States, 92835
  • Irvine Clinical Research Center, Irvine, California, United States, 92614
  • Pharmacology Research Institute, Los Alamitos, California, United States, 90720
  • National Research Institute – Huntington Park, Panorama City, California, United States, 91402
  • Anderson Clinical Research, Redlands, California, United States, 92374
  • Pacific Research Network, San Diego, California, United States, 92103
  • Univ of California San Francisco, San Francisco, California, United States, 94158
  • Syrentis Clinical Research, Santa Ana, California, United States, 92705
Back To Top